The mechanism of action of cyclosporin A and FK506 - PubMed (original) (raw)
Review
The mechanism of action of cyclosporin A and FK506
S L Schreiber et al. Immunol Today. 1992 Apr.
Abstract
CsA and FK506 are powerful suppressors of the immune system, most notably of T cells. They act at a point in activation that lies between receptor ligation and the transcription of early genes. Here, Stuart Schreiber and Gerald Crabtree review recent findings that indicate CsA and FK506 operate as prodrugs: they bind endogenous intracellular receptors, the immunophilins, and the resulting complex targets the protein phosphatase, calcineurin, to exert the immunosuppressive effect.
Similar articles
- Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
Zhu D, Cardenas ME, Heitman J. Zhu D, et al. Mol Pharmacol. 1996 Sep;50(3):506-11. Mol Pharmacol. 1996. PMID: 8794888 - Molecular and biological actions of cyclosporin A and FK506 on T cell development and function.
Holländer GA, Bierer BE, Burakoff SJ. Holländer GA, et al. Transfus Sci. 1994 Sep;15(3):207-20. doi: 10.1016/0955-3886(94)90133-3. Transfus Sci. 1994. PMID: 10155542 Review. - Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ, Michielsen EC, Verstappen J, Fasse E, Joosten I. Koenen HJ, et al. Transplantation. 2003 May 15;75(9):1581-90. doi: 10.1097/01.TP.0000053752.87383.67. Transplantation. 2003. PMID: 12792519 - Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation.
Clipstone NA, Crabtree GR. Clipstone NA, et al. Nature. 1992 Jun 25;357(6380):695-7. doi: 10.1038/357695a0. Nature. 1992. PMID: 1377362 - The mechanism of action of cyclosporin A and FK506.
Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR. Ho S, et al. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S40-5. doi: 10.1006/clin.1996.0140. Clin Immunol Immunopathol. 1996. PMID: 8811062 Review.
Cited by
- Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19.
Liu C, von Brunn A, Zhu D. Liu C, et al. Med Drug Discov. 2020 Sep;7:100056. doi: 10.1016/j.medidd.2020.100056. Epub 2020 Jul 16. Med Drug Discov. 2020. PMID: 32835213 Free PMC article. Review. - A Cleavable Scaffold Strategy for the Synthesis of One-Bead One-Compound Cyclic Peptoid Libraries That Can Be Sequenced By Tandem Mass Spectrometry.
Simpson LS, Kodadek T. Simpson LS, et al. Tetrahedron Lett. 2012 May 2;53(18):2341-2344. doi: 10.1016/j.tetlet.2012.02.112. Epub 2012 Mar 5. Tetrahedron Lett. 2012. PMID: 22736872 Free PMC article. - Immunophyllin ligands show differential effects on alcohol self-administration in C57BL mice.
Beresford T, Fay T, Serkova NJ, Wu PH. Beresford T, et al. J Pharmacol Exp Ther. 2012 Jun;341(3):611-6. doi: 10.1124/jpet.111.188169. Epub 2012 Feb 28. J Pharmacol Exp Ther. 2012. PMID: 22375069 Free PMC article. - A multiplexed proteomics approach to differentiate neurite outgrowth patterns.
Liu T, D'mello V, Deng L, Hu J, Ricardo M, Pan S, Lu X, Wadsworth S, Siekierka J, Birge R, Li H. Liu T, et al. J Neurosci Methods. 2006 Nov 15;158(1):22-9. doi: 10.1016/j.jneumeth.2006.05.010. Epub 2006 Jun 23. J Neurosci Methods. 2006. PMID: 16797718 Free PMC article. - The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
Periyasamy S, Warrier M, Tillekeratne MP, Shou W, Sanchez ER. Periyasamy S, et al. Endocrinology. 2007 Oct;148(10):4716-26. doi: 10.1210/en.2007-0145. Epub 2007 Jul 5. Endocrinology. 2007. PMID: 17615153 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources